Copyright
©The Author(s) 2016.
World J Gastrointest Surg. Mar 27, 2016; 8(3): 274-283
Published online Mar 27, 2016. doi: 10.4240/wjgs.v8.i3.274
Published online Mar 27, 2016. doi: 10.4240/wjgs.v8.i3.274
Table 1 Study characteristics
Ref. | Country | Date | Type | n | NOS (0-9) | Pre-operative infliximab use (w) | Age1 | Sex (m) | Steroids | Abscess |
Appau et al[7] | United States | 1998-2007 | Retrospective cohort | 389 | 7 | 12 | ||||
Infliximab | 35.8 (11.9) | 48.3% | 65% | 38% | ||||||
No infliximab | 36.8 (14.4) | 45.9% | 77% | 44% | ||||||
Canedo et al[10] | United States | 2000-2008 | Retrospective cohort | 225 | 7 | 12 | ||||
Infliximab | 26 (24.9-43.6) | 44% | NS | 37% | ||||||
No infliximab | 32 (29.4-41.9) | 51% | NS | 30% | ||||||
Colombel et al[11] | United States | 1998-2001 | Retrospective cohort | 270 | 7 | 8 | ||||
Infliximab | NS | NS | 36% | NS | ||||||
No infliximab | NS | NS | 42% | NS | ||||||
El Hussuna et al[17] | Denmark | 2000-2007 | Retrospective cohort | 369 | 7 | 12 | ||||
Infliximab | 33 (18-62) | NS | NS | 34% | ||||||
No infliximab | 37 (8-90) | NS | NS | 19% | ||||||
Kasparek et al[15] | Munich | 2001-2008 | Case control match | 96 | 7 | 12 | ||||
Infliximab | 35 (17-66) | 43% | 94% | NS | ||||||
No infliximab | 39 (17-68) | 50% | 94% | NS | ||||||
Kotze et al[23] | Brazil | 2007-2010 | Retrospective cohort | 76 | 7 | 4 | ||||
Infliximab | NS | NS | NS | NS | ||||||
No infliximab | NS | NS | NS | NS | ||||||
Marchal et al[18] | Netherlands | 1998-2002 | Case control match | 68 | 8 | 12 | ||||
Infliximab | 36 (16-73) | NS | 35% | 50% | ||||||
No infliximab | 38.7 (17-63) | NS | 35% | 41% | ||||||
Mascarenhas et al[16] | United States | 2003-2010 | Retrospective cohort | 93 | 6 | 12 | ||||
Infliximab | 35.6 (14.1) | 42% | 68% | NS | ||||||
No infliximab | 37 (14.1) | 60% | 44% | NS | ||||||
Myrelid et al[21] | Europe | 1989-2002 | Retrospective cohort | 298 | 6 | 8 | ||||
Infliximab | NS | 46% | NS | 20% | ||||||
No infliximab | NS | 36% | NS | 20% | ||||||
Nasir et al[20] | United States | 2005-2008 | Retrospective cohort | 370 | 8 | 8 | ||||
Infliximab | 38.2 (17-66) | 43% | 31% | NS | ||||||
No infliximab | 43.3 (17-77) | 41% | 45% | NS | ||||||
Nørgård et al[9] | Denmark | 2000-2010 | Retrospective cohort | 2293 | 6 | 12 | ||||
Infliximab | NS | 45% | 9% | NS | ||||||
No infliximab | NS | 41% | 14% | NS | ||||||
Syed et al[8] | United States | 2004-2011 | Retrospective cohort | 325 | 7 | 8 | ||||
Infliximab | 38.2 (13.9) | 34% | 40% | 8% | ||||||
No infliximab | 40 (14.3) | 45% | 35% | 9% | ||||||
Tay et al[19] | United States | 1998-2002 | Retrospective cohort | 100 | 7 | 8 | ||||
Infliximab | NS | NS | 0% | NS | ||||||
No infliximab | NS | NS | 18% | NS | ||||||
Uchino et al[22] | Japan | 2008-2011 | Retrospective cohort | 405 | 7 | 12 | ||||
Infliximab | 36 (14-72) | 73% | 37% | NS | ||||||
No infliximab | 37 (16-78) | 69% | 34% | NS | ||||||
Total | 5377 |
- Citation: Waterland P, Athanasiou T, Patel H. Post-operative abdominal complications in Crohn’s disease in the biological era: Systematic review and meta-analysis. World J Gastrointest Surg 2016; 8(3): 274-283
- URL: https://www.wjgnet.com/1948-9366/full/v8/i3/274.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v8.i3.274